Articles related to BIOMARKERS

A clinician review outlined how diagnostic confidence, staging, genetic risk, and imaging features inform patient selection for amyloid-targeting Alzheimer’s therapies.

The first participant was dosed in a Phase 3 trial of oral votoplam, as interim Phase 2 extension data suggested dose-dependent slowing of Huntington’s progression.

Multiple Alzheimer disease biomarkers showed accelerated age-related changes near age 70 in a Mayo Clinic Study of Aging cohort, identifying potential screening and monitoring windows.

Retrospective analysis of pediatric cancer survivors identified low overall CHIP prevalence, with antimetabolite therapy and methotrexate exposure emerging as the strongest treatment-associated signals.

Invasive mucinous adenocarcinoma carries elevated NRG1 fusion burden that standard DNA-based sequencing reliably misses, while an FDA-approved targeted therapy now exists for confirmed cases.

The FDA approved vepdegestrant for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after endocrine therapy progression, marking the first regulatory approval of a PROTAC drug.